Identity
SLU-PP-332 is a small-molecule ERR agonist, not a peptide.
Diet-induced obese and ob/ob mouse models.
Peptide library
SLU-PP-332
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The experiments concern an estrogen-related-receptor agonist in mice. Increased energy expenditure is a preclinical mechanism, not a human exercise substitute or verified weight-loss treatment.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Diet-induced obese and ob/ob mouse models.
What the sources found
Mouse experiments reported metabolic changes including increased energy expenditure and reduced fat accumulation; human weight-loss efficacy was not tested.
Diet-induced obese and ob/ob mouse models.
Regulatory scope
No jurisdiction-specific marketing authorization has been verified in this snapshot; study publication is not regulatory approval.
What remains unknown
These findings do not establish human efficacy, long-term safety, or equivalence to products sold under this name. This is a focused source snapshot, not an exhaustive clinical review.
How it works
SLU-PP-332 is a small-molecule ERR agonist, not a peptide.
Read the study-specific findings and limitations in Medical. Mechanistic activity does not establish a treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- The cited evidence does not establish comprehensive human adverse-event rates.
Contraindications
- A complete clinical contraindication profile has not been established in this review.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Findings
Mouse experiments reported metabolic changes including increased energy expenditure and reduced fat accumulation; human weight-loss efficacy was not tested.
Diet-induced obese and ob/ob mouse models.
References
Billon et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. 2024.
PMID: 37739806
Synthetic ERR agonist and exercise capacity in preclinical models. 2023.
PMID: 36988910
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.